MENU

Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever

Warimwe, GM; Gesharisha, J; Carr, BV; Otieno, S; Otingah, K; Wright, D; Charleston, B; Okoth, E; Elena, LG; Lorenzo, G; Ayman, EB; Alharbi, NK; Al-dubaib, MA; Brun, A; Gilbert, SC; Nene, V; Hill, AVS

SCIENTIFIC REPORTS
2016
VL / 6 - BP / - EP /
abstract
Rift Valley Fever virus (RVFV) causes recurrent outbreaks of acute life-threatening human and livestock illness in Africa and the Arabian Peninsula. No licensed vaccines are currently available for humans and those widely used in livestock have major safety concerns. A 'One Health' vaccine development approach, in which the same vaccine is co-developed for multiple susceptible species, is an attractive strategy for RVFV. Here, we utilized a replication-deficient chimpanzee adenovirus vaccine platform with an established human and livestock safety profile, ChAdOx1, to develop a vaccine for use against RVFV in both livestock and humans. We show that single-dose immunization with ChAdOx1-GnGc vaccine, encoding RVFV envelope glycoproteins, elicits high-titre RVFV-neutralizing antibody and provides solid protection against RVFV challenge in the most susceptible natural target species of the virus-sheep, goats and cattle. In addition we demonstrate induction of RVFV-neutralizing antibody by ChAdOx1-GnGc vaccination in dromedary camels, further illustrating the potency of replication-deficient chimpanzee adenovirus vaccine platforms. Thus, ChAdOx1-GnGc warrants evaluation in human clinical trials and could potentially address the unmet human and livestock vaccine needs.

AccesS level

DOAJ Gold, Green Published

Mentions data

PAPER MENTIONS
Immunology
  •   Twitter
  • 28
  •   Wikipedia
  • 1
  •   News
  • 12
  •   Policy
  • 0

Mentions Chart

Influratio by dimension
  • Twitter
  • Wikipedia
  • News
  • Policy
PAPER MENTIONS
  •   Twitter
  • 28
  •   Wikipedia
  • 1
  •   News
  • 12
  •   Policy
  • 0
PROYECTO FINANCIADO POR PLAN NACIONAL DE INVESTIGACIÓN AGENCIA ESTATAL DE INVESTIGACIÓN, MINISTERIO DE CIENCIA E INNOVACIÓN. PID2019-109127RB-I00